ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2655

Therapeutic Effect Of β2GPI and Its Synthetic derivative  Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation

Miri Blank1, Silvia S. Pierangeli2, Honorio Torres-Aguilar3 and Yehuda Shoenfeld4, 1Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, 2Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 3National Center for Blood Transfusion, Mexico City, Mexico, 4Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome, autoantibodies, autoimmune diseases, dendritic cells and tolerance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: The importance of beta-glycoprotein I (beta2GPI)-specific CD4+ T cells in the development of pathogenic processes in patients with antiphospholipid syndrome (APS) and APS mice models is well established. Tolerogenic dendritic cells (tDCs) have the potential to control the outcome of autoimmunity by modulating the immune response. Previously we showed that human tDCs induced  with IL-10 and TGFbeta1, loaded with beta2GPI ameliorated effector/memory CD4+ T cells response  in patients with APS in-vitro (Ann Rheum.Dis 2012). The aim of this study was to uncover the mechanisms that define the tolerogenic effect of beta2GPI or beta2GPI synthetic derivatives specific tDCs on experimental APS.

Methods:   tDCs were generated in-vitro from naïve mice bone marrow cells in the presence of TGFbeta  and IL-10, cDCs were supplemented with GM-CSF. All the DCs were LPS maturated, pulsed with beta2GPI or beta2synthetic derivatives control peptide and candidin and phenotyped by FACS.  miRNA expression were defined by RT-PCR and MAPKs by MAPKs protein-arrays. beta2GPI  T cell response to tDCs and cDCs by CFSC and FACS analyses. The tDCs and cDCs were subjected subcutaneously into mice with experimental APS induced by beta2GPI. CD4+CD25+FOXP3+ Treg cells were analyzed by FACS. Adoptive transfer experiments were conducted by passive transfer of Tregs from the tDCs –injected mice to APS mice. Cytokine expression of IFNgamma, IL-17, TGFbeta and IL-10 by RT-CR. 

Results: tDCs expressed miRNA 23b, 142-3p and 221, whereas  cDCs  were characterized in expression of miRNA 146a and miRNA155. tDCs  specific to beta2GPI and its synthetic derivative were able to decrease  b2GPI  response manifested by decreased beta2GPI  T cell response by 75%-87% while cDCs did not show any significant response, p<0.001.  Moreover, we were able to show inhibition of circulating anti-beta2GPI  antibodies titers (p<0.002) and inhibition of fetal loss by 67% was documented in tDCs recipient APS mice in comparison to 8% in the cDCs recipient mice , p<0.02. Enhanced expression of CD4+CD25+FOXP3+Tregs by 21% in tDCs injected mice in comparison to 5% in the cDCs injected APS mice was exemplified by FACS. Reduced expression of IFNgamma and L-17 by 5.2 times and enhanced expression of TGFbeta and IL-10  by 6.8 fold was illustrated by RT-PCR. A significant amelioration of  all the above parameters were noticed as well in the Treg transferred -APS recipient mice (e.g decreased beta2GPI T cell response, circulating anti-beta2GPI antibodies, and IFNgamma/IL-17). tDCs uploaded with beta2GPI had beneficial effect on the therapeutic properties than the beta2GPI synthetic derivatives, p>0.05. 

Conclusion: beta2GPI tDCS have the potential to ameliorate experimental APS by upregulation of Tregs and proinflammatory cytokines. beta2GPI tDCS may offer a novel approach for developing personalized therapy for APS patients.


Disclosure:

M. Blank,

NON,

2;

S. S. Pierangeli,

non,

2;

H. Torres-Aguilar,
None;

Y. Shoenfeld,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-effect-of-%ce%b22gpi-and-its-synthetic-derivative-loaded-tolerogenic-dendritic-cells-in-experimental-antiphospholipid-syndrome-is-associated-with-mirna-23b-142-3p-and-221-expressio/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology